Participated in Spot Biosystems' $40M Series A for a non-viral extracellular vesicle gene therapy platform.
Spot Biosystems develops non-viral gene therapies using extracellular vesicles for safer treatments, starting with Duchenne muscular dystrophy
Spot Biosystems develops non-viral gene therapies using extracellular vesicles for safer treatments, starting with Duchenne muscular dystrophy. Their platform aims to improve safety and efficacy.